Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Tiotropium 18 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This is a multicentre, randomized, blinded, double dummy, parallel group study to evaluate the efficacy and safety of UMEC inhalation powder\[ (62.5 microgram (mcg) once daily (QD)\] when administered via a novel Dry Powder Inhaler compared with tiotropium (18 mcg QD) administered via a HANDIHALER® inhaler over a treatment period of 12 weeks (24 weeks in Germany) in subjects with chronic obstructive pulmonary disease (COPD). At the end of the run-in period, subjects who meet the randomization criteria will be randomized to receive UMEC 62.5 mcg administered via novel dry powder inhaler(nDPI) + Placebo administered via HANDIHALER inhaler OR Tiotropium 18 mcg administered via HANDIHALER inhaler + Placebo administered via nDPI in a 1:1 ratio. There will be up to 8 clinic visits conducted on an outpatient basis at Pre-Screening (Visit 0), Screening (Visit 1), a 7 to 14 day run-in period, randomization at Day 1 (Visit 2), and after randomization at Day 2 (Visit 3), Day 28 (Visit 4), Day 56 (Visit 5), Day 84 (Visit 6) and Day 85 (Visit 7). For subjects enrolled in Germany, there will be an additional 3 visits at Day 112 (Visit 8), Day 140 (Visit 9) and Day 168 (Visit 10). The total duration of subject participation in the study will be approximately 15 weeks (27 weeks in Germany). The primary endpoint of the study is clinic visit trough forced expiratory volume in one second (FEV1) on treatment Day 85. All subjects will have spirometry performed at clinic Visits 1 though 7. Trough spirometry will be obtained 23 and 24 hours after the previous day's dose of blinded study medication at Visits 3 to 7.

HANDIHALER is a registered trademark of Boehringer Ingelheim Pharma GmbH \& Co. KG.


Options:
A: Arm Label: Umeclidinium 62.5 mcg + placebo; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium, Drug: Umeclidinium matching placebo | Arm Label: Tiotropium 18mcg + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Tiotropium matching placebo | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Umeclidinium matching placebo; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium 18mcg + placebo | Intervention Type: DRUG; Name: Tiotropium matching placebo; Assigned to Arm(s): Tiotropium 18mcg + placebo
B: Arm Label: Umeclidinium 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium | Arm Label: Glycopyrronium 44 mcg; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg | Intervention Type: DRUG; Name: Glycopyrronium; Assigned to Arm(s): Glycopyrronium 44 mcg
C: Arm Label: UMEC/VI 125/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC/VI 125/25 mcg | Arm Label: UMEC/VI 62.5/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC/VI 62.5/25 mcg | Arm Label: UMEC 125 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC 125 mcg | Arm Label: UMEC 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC 62.5 mcg | Arm Label: VI 25 mcg; Type: EXPERIMENTAL; Interventions: Drug: VI 25 mcg | Intervention Type: DRUG; Name: UMEC/VI 125/25 mcg; Assigned to Arm(s): UMEC/VI 125/25 mcg | Intervention Type: DRUG; Name: UMEC/VI 62.5/25 mcg; Assigned to Arm(s): UMEC/VI 62.5/25 mcg | Intervention Type: DRUG; Name: UMEC 125 mcg; Assigned to Arm(s): UMEC 125 mcg | Intervention Type: DRUG; Name: UMEC 62.5 mcg; Assigned to Arm(s): UMEC 62.5 mcg | Intervention Type: DRUG; Name: VI 25 mcg; Assigned to Arm(s): VI 25 mcg
D: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 62.5/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 62.5mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 62.5/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 62.5mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A